We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Venture Life Group Plc | LSE:VLG | London | Ordinary Share | GB00BFPM8908 | ORD 0.3P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 0.13% | 38.25 | 38.00 | 38.50 | 38.25 | 38.25 | 38.25 | 27,379 | 08:00:08 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Misc Retail Stores, Nec | 51.41M | 921k | 0.0072 | 53.06 | 48.53M |
Date | Subject | Author | Discuss |
---|---|---|---|
07/8/2024 13:06 | I reckon Slater is picking up stock.. Net debt reduction was very impressive. | celeritas | |
06/8/2024 11:24 | Overall a good trading update but disappointing to see revenue flat at £23.5m. VLG brands put in a storming performance +27% in H1 23, so this was always going to be a headwind. Broker forecast is FY revenue £55m so based on 45/55% split, H1 ideally should have come in around £24.75 which is a tad behind expectations. Revenue of £31.5m is required in H2, but management states it has good visibility with further new listings and new international business (esp Jaguar Health) coming on stream. Net debt reduced by £3m to £10.7m despite investment into medical device Regs and new product development. Cavendish estimates FY net debt at £9.2m by FY end, but today suggests this could come in £770K lower at £8.5m. M&A should be on the cards again soon as the CEO says 'Some really good opportunities are out there'. Lots to like here at a valuation that fails to reflect the bright growth prospects IMHO. | eagle eye | |
06/8/2024 07:16 | Promise of future growth. Customer brands down 6% with inflation the other way not good. VLG up 6% but will need to be up 17% 2nd half to meet 55m expectations.. Good to see margin continue to improve and positive net debt story continues..I would expect a modest drop in share price until hinted at strategic investment comes through, maybe before interims. | chester9 | |
06/8/2024 06:56 | Cash and debt Solid free cashflow generation in the Period resulted in a further net debt reduction of approximately £3.0m to £10.7m (31 December 2023: £13.7m). Group leverage is anticipated to fall below 0.8x by the end of the year (31 December 2023: 1.3x) and presents more opportunity to explore strategic investment through attractive and accretive M&A. | celeritas | |
06/8/2024 06:34 | Positive & in line H1'24 trading update today from consumer healthcare products firm. All the news & commentary here. Brief note: CEO Interview - | brummy_git | |
06/8/2024 06:05 | Surprised the numbers weren't higher given the confidence of the statement A pullback today but further rises over the coming months to accommodate the increased second half numbers and performance | basem1 | |
31/7/2024 13:19 | Yes thanks ee | thedudie | |
31/7/2024 13:08 | My pleasure. It's far more efficient than everyone contacting VLG individually :-)) | eagle eye | |
31/7/2024 12:42 | Thanks for following up on the TU date, Eagle - much appreciated, Lammy. | lammylover | |
31/7/2024 11:49 | VLG have replied and the TU will now be beginning of August. I've asked be notified the day before, so will post again if I hear anything. | eagle eye | |
31/7/2024 08:13 | I've contacted VLG this morning to find out what's happening with the TU. I'll post here when I receive a reply. | eagle eye | |
31/7/2024 07:15 | Something else happening to delay it? Sorry I know that's obvious!! | bagpuss67 | |
30/7/2024 08:33 | update tomorrow apparently | wooster4 | |
29/7/2024 14:08 | They have got the debt down quicker than I thought likely so I would want them in the next few months to start leveraging the debt facility they have by buying some new brands. If they don't and the debt has been reduced into single figure millions by end of year then they will be on borrowed time. | thedudie | |
29/7/2024 12:15 | I do think vlg are on borrowed time. They have built up a number of brands now, collected them together for a larger suiter who will take vlg's products and push them into many more markets much quicker than vlg. APH for one, vlg already manufacture a number of products for them never even mind bigger outfits. The scope is vast and I'm sure bigger co's will see that. | celeritas | |
29/7/2024 11:57 | VLG were appointed as second manufacturer of Alliance Pharma’s key brand Kelo-cote around 2020 I believe. | celeritas | |
29/7/2024 06:50 | Good read from Aph for the kelocote and up 20% which I believe we manufacture for them. | deanowls | |
29/7/2024 06:09 | Had hoped for the update this am.. | bagpuss67 | |
25/7/2024 16:03 | I'm fully loaded! | bagpuss67 | |
25/7/2024 15:31 | A tip In itself as he will have the boards ear | basem1 | |
25/7/2024 15:05 | Slater Investments increases holding from 18% to 19%. Hopefully a good omen for next week's trading update. | eagle eye | |
17/7/2024 18:19 | The key executives have a million shares each under option in the 30s….I hope they make loads of money. They are certainly incentivised to find well priced acquisitions and to extend the products they have. | 1jat | |
17/7/2024 09:29 | Relative strength has been good, but 12 month rolling prospective PER still only x 8. In future VLG will report private label brands separately, but this did £2.4m last year and is likely to 'double in size every year for the next two or three years' so could be 10 to 15% of revenue in pretty short order. Cavendish forecasts net debt falling to £1.9m in 18 months time, but VLG will have been on the acquisition trail by then. Still early days, but still attractively valued IMHO :-)) | eagle eye | |
17/7/2024 08:30 | Share price has been strong this year - up about 50%. Trading update was issued last year on 31st july with half yarly results announced in late Sept If there is coninuing good news in these anouncements,the price rise could continue for the rest of the year. | camerongd53 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions